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Apoptosis plays a crucial role in embryonic development and
tissue homeostasis (White, 1996). Regulation of apoptosis
involves a large number of genes that can be classified into three
broad categories: (1) genes that primarily suppress apoptosis, such
as bcl-2, bfl-1, brag-1, ced-9, BHRF-6; (2) genes that promote
apoptosis such as bax, bak, bid, caspases family; and (3) genes
upstream of apoptosis, including Fas/Fas ligand, p53, p63, myc,
P21WAF1/CIPI (Boise et al, 1993; Henderson et al, 1993; Hengartner
and Horvitz, 1994; Boyd et al, 1995). Apoptosis in mammalian
cells is controlled by equilibrium between suppressor and
promoter gene products (Oltvai and Korsmeyer 1994; Wang et al,
1999a). Bcl-2, the first identified anti-apoptotic gene product
(Reed, 1994), plays an important role in the regulation of apop-
tosis. Although the functional significance of bcl-2 phosphoryla-
tion/dephosphorylation remains controversial, several reports have
suggested that this post-translational modification may be a
possible mechanism involved in the bcl-2 mediated apoptosis
(Haldar et al, 1995; Haldar et al, 1997; Yamamoto et al, 1999). 
Vinorelbine is a third-generation vinca alkaloid targeting micro-
tubules with broad anticancer activity in man and is commercially
available in many parts of the world (Budman, 1997). Our recent
study showed synergism or antagonism with vinorelbine and
paclitaxel were both sequence dependent and cell line-specific
(Budman et al, 2000). In contrast with taxanes that are known to
interact with polymerized tubulin and prevent depolymerization,
vinca alkaloids interact with monomeric tubulin and prevent poly-
merization. Previous studies have demonstrated that these micro-
tubule-targeting agents promote apoptosis in cancer cells
(Donaldson et al, 1994; Haldar et al, 1995). A suggested mecha-
nism of anti-cancer activity of paclitaxel has been loss of bcl-2
function as a consequence of phosphorylation by activated raf-1
kinase (Blagosklonny et al, 1995; Blagosklonny et al, 1996;
Blagosklonny et al, 1997). MAP kinases also have been shown to
be involved directly or indirectly in the regulation of bcl-2 phos-
phorylation (Avruch et al, 1994; Nishio et al, 1995; Lieu et al,
1998; Wang et al, 1998a; Attalla et al, 1998). In this study, we
evaluated the effect of vinorelbine and paclitaxel on the activity of
extracellular signal-regulated protein kinase2 (ERK2), a member
of MAP kinase, and its possible role in the induction of bcl-2
phosphorylation and apoptosis in MCF-7 cells. 
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Summary The effects of vinorelbine and paclitaxel on the activity of extracellular signal-regulated protein kinase2 (ERK2), a member of MAP
kinase, and its role in the induction of bcl-2 phosphorylation and apoptosis were evaluated in MCF-7 cells. We demonstrated that ERK2 was
activated rapidly by vinorelbine, and was inhibited by either paclitaxel or estramustine. A 3-fold increase of ERK2 kinase activity was observed
within 30 min when MCF-7 cells were treated with 0.1 µ M vinorelbine. In contrast, the same treatment with paclitaxel resulted in a significant
decrease of ERK2 kinase activity. We also demonstrated that elevated bcl-2 phosphorylation induced by vinorelbine is paralleled by decrease
of a complex formation between bcl-2 and bax, cleavage of poly (ADP) ribose polymerase (PARP) protein, activation of caspase-7, and
apoptosis. The levels of bcl-2 phosphorylation, bax, and PARP were not significantly affected by 2′ -amino-3′ -methoxyflavone (PD 98059), an
ERK kinase specific inhibitor. Thus, our data suggest that the apoptosis induced by vinorelbine in MCF-7 cells is mediated through the bcl-2
phosphorylation/bax/caspases pathways, and that activation of ERK2 by vinorelbine does not directly lead to the drug-mediated apoptosis.
Since decrease of PARP occurred quickly following the treatment of MCF-7 cells with either 0.1 µ M of vinorelbine or paclitaxel, this protein
may serve as an early indicator of apoptosis induced not only by DNA damaging agents, but also by antimicrotubule drugs. © 2001 Cancer
Research Campaign http://www.bjcancer.com
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Reagents 
Antibodies against c-raf-1, ERK2, bcl-2, bax, caspase-7, and β -
actin as well as anti-rabbit IgG-HRP were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). PARP antibody that
only recognized original form (116 kDa) was purchased from
Enzyme System Products (Livermore, CA), and PARP antibody
that can recognize both original (116 kDa) and degradation form
(83 kDa) was purchased from Boehringer Mannheim (Germany).
Protein A and λ protein phosphatase (λ PPase) was obtained from
Calbiochem (San Diego, CA). A Western blotting detection kit
was purchased from Amersham (Arlington Heights, IL). Reagents
for SDS-PAGE and protein determination were obtained from
Bio-Rad, (Richmond, CA). RPMI-1640 medium and fetal bovine
serum (FBS) were purchased from Gibco BRL Life Technologies,
Inc. (Gaithersburg, MD). Histone III-S (approximately 30 kDa),
and myelin basic protein (18 kDa), as well as paclitaxel and other
chemicals were purchased from the Sigma Chemical Company (St
Louis, MO). γ -32P-ATP and 32P-orthophosphate were purchased
from NEN Life Science Products Inc. (Boston, MA). Vinorelbine
(NVB) was kindly provided by Glaxo Wellcome Inc. (Research
Triangle, NC). 
Cell culture 
The breast cancer line MCF-7 was purchased from the American
Type Culture Collection (Rockville, MD). Cells were maintained
under conditions as described previously (Wang et al, 1996). The
cell lines used for experiments were less than 30 passages in
length. 
Cell treatment 
MCF-7 cells at 65–75% confluence in RPMI-1640 medium
containing 10% FBS were treated with indicated concentrations of
vinorelbine or paclitaxel for indicated periods of time, or for 24 h.
The cells were harvested and then washed with cold PBS. Total
cellular proteins were extracted as described previously (Wang
et al, 1994). 
Western blotting assay 
Fifty to 100 µ g of cellular extracts were separated by stack
4%/10% SDS-PAGE, or by 4/20% gradient SDS-PAGE, electro-
transferred to nitrocellulose filters, and probed with bcl-2 or bax-
specific antibody using standard techniques (Wang et al, 1994).
Quantitation by densitometry of the ECL films was done using an
Imaging Densitometer Model GS-700 (Bio-Rad Lab, Hercules,
CA). 
Metabolic labeling and λ protein phosphatase
treatment 
MCF-7 cells grown exponentially were treated for 16 h with
0.2 µ M of paclitaxel in phosphate-free RPMI-1640 medium
containing 10% FBS, and metabolically labelled for 4 h by the
addition of 200 µ Ci/ml of 32P-orthophosphate to the culture. The
cells were harvested, washed and total proteins extracted with cell
lysing buffer PBSTDS (0.058 M NaHPO4, 0.017 M NaHPO4,
0.068 M NaCl, 1% Trition X-100, 0.5% sodium deoxycholate and
0.1% sodium dodecyl sulfate) containing a cocktail of proteinase
inhibitors (1 mM PSMF, 5 µ g/ml leupeptin, 10 µ g/ml aprotinin, and
25 µ g/ml bacitracin) and phosphatase inhibitors (50 mM NaF and
1 mM sodium orthovanadate). The protein extracts were incubated
with bcl-2 antibody at 4˚C for 1 h followed by addition of protein
agarose A, and the immuno-reaction mixtures were incubated at
4˚C overnight with gentle rotation. After 4 washes with PBSTBS,
the immunoprecipitates were resuspended in λ PPase reaction
buffer supplied by the manufacturer and incubated with 500 U of
λ PPase for 30 min at 30˚C in the presence or absence of phos-
phatase inhibitors (50 mM NaF, 2 mM sodium orthovanadate, 5
mM EDTA, and 5 mM EGTA). Protein sample buffer was then
added, and after boiling for 2 min the reaction mixtures were
subjected to Western blot analysis. 
Flow cytometry 
MCF-7 cells at exponential growth were exposed to 0.1 µ M of
vinorelbine or paclitaxel for 48 h. The cells were harvested,
washed with PBS and fixed with 70% ethanol for 1 h in ice. The
cells were then treated with 500 µ g of RNase for 30 min at 37˚C,
stained with propidium iodide, and analysed by the FACSVantage
(Becton, Dickinson and Company, Franklin Lakes, NJ) for cell
cycle assay. 
ERK2 kinase assay 
The ERK2 kinase assay was performed as previously described
(Patton et al, 1998). Briefly, drug treated cells were harvested,
washed once with ice-cold PBS and once with kinase buffer (20
mM HEPES, pH 7.4, 20 mM MgCl2) in the presence of cocktail
proteinase inhibitors (1 mM PSMF, 5 µ g/ml leupeptin, 10 µ g/ml
aprotinin, and 25 µ g/ml bacitracin) (Wang et al, 1995; Patton et al,
1998). Cells were lysed in PBSTDS (0.058 M NaHPO4, 0.017 M
NaHPO4, 0.068 M NaCl, 1% Trition X-100, 0.5% sodium deoxy-
cholate and 0.1% sodium dodecyl sulfate), and 100 µ g of the
proteins were immunoprecipitated overnight at 4˚C with antibody
specifically against EKR2 in the presence of cocktail proteinase
inhibitors. After three washes with PBSTDS and one wash with
kinase buffer, the immuno-purified protein was incubated for 30
min in 50 µ l kinase buffer containing 0.25 mg/ml of myelin and
100 µ M/0.5 µ Ci [γ -32P]-ATP at room temperature. The reaction
was terminated by adding protein sample buffer and boiled for
1 min. Kinase activity was calculated from the amount of phos-
phorylated substrate formed using liquid scintillation counting as
described previously (Sommercorn et al, 1987; Wang et al, 1995).
Alternatively, an aliquot of the substrate was subjected to 4%/10%
stack SDS-PAGE (Nishio et al, 1995), and the phosphorylated
substrate was analyzed by autoradiography, and quantitated by an
imaging densitometer. 
RESULTS 
Paclitaxel-mediated induction of bcl-2 phosphorylation 
It has been previously demonstrated that paclitaxel stimulates bcl-
2 phosphorylation in various cell lines (Yamamoto et al, 1999;
Blagosklonny et al, 2000). To examine whether this is also the case
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for 16 h in phosphate-free RPMI-1640 medium containing 10%
FBS. The cells were then metabolically labeled with 32P-orthophos-
phate at 200 µ Ci/ml for 4 h. Immunoprecipitation of cell extracts
from treated and untreated cells was performed in the presence or
absence of λ protein phosphatase (λ PPase) ± phosphatase inhibitors.
As shown in Figure 1, treatment of paclitaxel significantly increased
upper protein bands that were diminished by incubation with
λ PPase (lanes 2, and 3). Addition of phosphatase inhibitors (50
mM NaF, 2 mM of sodium orthovanadate, 5 mM EDTA, and 5
mM EGTA) to the reaction mixture reversed those dephosphory-
lated proteins (lane 4). These data were consistent with the
previous report (Yamamoto et al, 1999), and demonstrated that like
other cell lines, paclitaxel is also able to induce bcl-2 phosphoryla-
tion in MCF-7 cells. 
Induction of bcl-2 phosphorylation and bax expression 
Exposure of MCF-7 cells grown exponentially to either 0.1 µ M
of vinorelbine or 0.1 µ M of paclitaxel resulted in significant
induction of bcl-2 phosphorylation (Figure 2A and Figure 3A). An
approximately two-fold increase of bcl-2 phosphorylation, as
reflected by the elevated ratio of phosphorylated-to-dephosphory-
lated bcl-2 proteins, occurred as early as 30 min following the
treatment of MCF-7 cells with vinorelbine (Figure 2A). A hyper-
phosphorylated bcl-2 band was detectable at 7 h, and significantly
increased at 24 h. In contrast, the significant increase in bcl-2 phos-
phorylation by paclitaxel occurred at 7 h with a hyper-phosphory-
lated form of bcl-2 (Figure 1B). Similar induction of bcl-2
phosphorylation was also observed in cells treated with docetaxel
(data not shown), but not with estramustine (Wang et al, 1999b). 
The effects of vinorelbine or paclitaxel on the expression of bax
were found to be time-dependent as illustrated in Figure 2B and
Figure 3B. Both vinorelbine and paclitaxel at a concentration of
0.1 µ M caused inhibition of bax expression in MCF-7 cells. A
significant increase in the level of bax was observed at 24 h after
the treatment with 0.1 µ M of vinorelbine (Figure 2B). In contrast,
the reduced level of bax in paclitaxel-treated cells recovered begin-
ning at 3 h, and returned to the normal level at 7 h (Figure 3B).
Induction of bcl-2 phosphorylation is followed by loss of its
ability to form heterodimers with bax (Haldar et al, 1996).
Therefore, the complex formation between bcl-2 and bax was
examined. As shown in Figure 4, vinorelbine significantly
Effect of vinorelbine on ERK2 kinase 1405
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Figure 1 Induction of bcl-2 phosphorylation by paclitaxel. MCF-7 cells
grown exponentially were treated or untreated for 16 h with 0.2 µ M of
paclitaxel in phosphate-free RPMI 1640 medium containing 10% FBS. The
cells were then metabolically labelled for 4 h by addition of 200 µ Ci/ml 32P-
orthophosphate to the culture. The cells were harvested, washed and total
proteins extracted for Western blot assay using bcl-2 antibody as described
in ‘Materials and Methods’. Lane 1, the immunoprecipitate was from
untreated MCF-7 cells; Lane 2, from paclitaxel-treated cells; Lanes 3 and 4,
the immunoprecipitates from paclitaxel-treated cells were resuspended in
λ PPase reaction buffer and incubated with 500 U of λ PPase for 30 min at
30˚C in the absence (lane 3) or presence (lane 4) of phosphatase inhibitors
(50 mM NaF, 2 mM of sodium orthovanadate, 5 mM EDTA, and 5 mM EGTA) 
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Figure 2 Induction of bcl-2 phosphorylation in MCF-7 cells by vinorelbine. MCF-7 cells grown exponentially were exposed to 0.1 µ M of vinorelbine for
indicated periods of time. The cells were harvested, washed, and total protein extracted. Fifty µ g proteins were subjected to 4%/20% gradient SDS-PAGE
followed by Western blotting using specific antibodies against bcl-2, and bax, respectively (upper panel). The same membrane was stripped and re-probed with
β -actin for loading control. The levels of bcl-2 and bax were measured from ECL film by Model GS-700 Imaging Densitometer (lower panels) and normalized by
β -actin. *: P < 0.05; **: P < 0.01 decreased formation of bcl-2/bax heterodimers after the induction
of bcl-2 phosphorylation, even though the level of bax protein was
increased at that time (24 h). A similar observation has been
reported in paclitaxel-, vincristine-, and vinblastine-treated cells
(Haldar et al, 1996; Srivastava et al, 1998). 
Induction of apoptosis by vinorelbine and paclitaxel
In contrast to the finding of elevated bcl-2 phosphorylation, subse-
quent to exposure of MCF-7 cells to either 0.1 µ M of vinorelbine
or paclitaxel, the level of PARP (116 kDa) decreased significantly
and rapidly. Approximately 44% decrease of PARP protein
occurred within 30 min after the exposure, and a 73% decrease at
7 h, which was maintained at lower levels for up to 24 h (Figure 5A).
The decreased PARP p116 paralleled its increase of degradation
form p83 (Figure 5B). Since MCF-7 has no caspase 3, but caspase
7 has been indicated to be involved in the paclitaxel-induced
PARP degradation and apoptosis (Panvichian et al, 1999) we
examined caspase 7 activity in MCF-7 cells exposed to either
vinorelbine or paclitaxel. As expected, a p20 active form of
casepase 7 activity in MCF-7 cells exposed to either vinorlbine or
paclitaxel. As expected, a p20 active form of caspase-7 was
observed only in drug-treated cells (Figure 5B), which paralleled
DNA fragmentation as measured by DNA agarose electrophoresis
(Figure 5B, lower panel).
In addition, a significant apoptotic induction and G2+M arrest
by both vinorelbine and paclitaxel was also observed in MCF-1
cells. As shown in Figure 5C, approximately 20% of the cells
became apoptotic after 48 h exposure to 0.1 µ M of either vinorel-
bine or paclitaxel.
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Figure 3 Effect of paclitaxel on apoptotic related protein expression/phosphorylation in MCF-7 cells. MCF-7 cells at exponential growth were treated with
0.1 µ M of paclitaxel for indicated periods of time. The cells were harvested, washed, and total protein extracted. Fifty µ g of proteins were separated by 4%/20%
gradient SDS-PAGE and electro-transferred to nitrocellulose membrane. Bcl-2 and bax proteins were then immuno-detected by Western blotting using specific
antibodies (upper panel). The same membrane was stripped and re-probed with β -actin for loading control. The levels of bcl-2 and bax were measured from
ECL film by Model GS-700 Imaging Densitometer and normalized by β -actin (lower panels). *: P < 0.05; **: P < 0.01 
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Figure 4 Inhibition of the complex formation between bcl-2 and bax by
vinorelbine in MCF-7 cells. MCF-7 cells, grown exponentially, were treated
with indicated concentrations of vinorelbine for 24 h. The cells were
harvested, washed, and proteins extracted. One hundred µ g of proteins were
immunoprecipitated with bax-specific antibody at 4˚C overnight in the
presence of protein agarose A + G. The precipitates were subjected to
Western blotting assay using specific antibodies against either bcl-2 and or
Bax (upper panel). The ratio of bcl-2/bax was calculated from density of ECL
film obtained by Model GS-700 Imaging Densitometer (lower panel). 
*: P < 0.01 Differential effect between vinorelbine and paclitaxel on
ERK2 kinase activity
MAP kinase may be involved in the regulation of apoptosis (Wang
et al, 1998b; Wang et al, 1999a), and may indirectly lead to bcl-2
phosphorylation (Avruch et al, 1994). To explore this possibility, the
effects of exposure to either 0.1 µ m vinorelbine or paclitaxel on
KRK2 kinase activity were examined. As shown in Figure 5, ERK2
kinase activity, as represented by the levels of phosphorylated-myelin
basic protein, was stimulated rapidly by vinorelbine (panel A), but
was inhibited by paclitaxel (panel B) or estramustine (data not
shown). An approximately 3-fold increase of KRK2 kinase activity
was observed within 30 min in MCF-7 cells treated with 0.1µ m
vinorelbine. The maximal activation occurred at 1 h with a 4-fold
increase, and the enzyme activity was maintained at higher levels
for up to 24 h. In contrast, treatment with 0.1 µ M paclitaxel
resulted in a decrease of ERK2 kinase activity within 30 min, with
significant inhibition (65%, P < 0.05) occurring at 1 h, followed by
recovery of up to 7 h. Neither the activation nor inhibition of
ERK2 kinase paralleled the increase in the level of phosphorylated
bcl-2 induced by vinorelbine or paclitaxel, as shown in Figure 1. 
No link between bcl-2 phosphorylation, bax expression, and
ERK2 kinase activation induced by vinorelbine was demonstrated,
as shown in Figure 6. No significant changes in the levels of either
phosphorylated-bcl-2 or bax or PARP proteins were observed
when cells were treated for 24 h with 0.1 µ M of vinorelbine in the
absence or presence of various concentrations (1.0–10.0 µ M) of
2´-amino-3´-methoxyflavone, within which a concentration-
dependent inhibition of PD 98059 on MAP kinase activity has
been observed (data not shown) that was consistent with previous
report (PD 98059, IC50 = 2.0–7 µ M (Alessi et al, 1995). In
Effect of vinorelbine on ERK2 kinase 1407
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Figure 5 Induction of apoptosis by vinorelbine and paclitaxel in MCF-7 cells. (A) Decrease in the level of PARP p116 following treatment with vinorelbine or
paclitaxel. MCF-7 cells grown exponentially were exposed to 0.1 µ M of vinorelbine or paclitaxel for indicated periods of time. The cells were harvested, washed,
and total proteins extracted for Western blot analysis using antibodies against PARP or β -actin for loading control. The level of PARP was measured from ECL
film by Model GS-700 Imaging Densitometer and normalized by β -actin (lower panels). *: P < 0.05; **: P < 0.01 
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(B) Cleavage of PARA, activation of caspase-7 and DNA fragmentation
induced by paclitaxel and vinorelbine. MCF-7 cells grown exponentially were
treated for 24 h with indicated concentrations of either paclitaxel or
vinorelbine. The cells were harvested, washed, and total proteins or DNA
were extracted for determination of cleavage of PARA, or activation of
caspase-7 by Western blot analysis or DNA fragmentation by DNA agarose
gel electrophoresis, as described in ‘Materials and Methods’ addition, no phosphorylated bcl-2 protein bands were observed when
immuno-purified bcl-2 was directly incubated with immuno-purified
MAP kinase. 
DISCUSSION 
Antimicrotubule agents, both polymerizing agents and depolymer-
izing drugs, have apoptosis-inducing activity (Donaldson et al,
1994) that is believed to result in the inactivation of bcl-2 function
through phosphorylation (Haldar et al, 1995; Haldar et al, 1997;
Srivastava et al, 1998) at serine-70 and serine-87 (Basu and Haldar
1998). Our study demonstrates that, analogous to paclitaxel,
vinorelbine significantly and rapidly induces bcl-2 phosphoryla-
tion. The decrease of complex formation between bcl-2 and bax is
also observed at 24 h after the exposure, even though the level of
bax at that time is higher than that of untreated control, which is
consistent with previous reports (Haldar et al, 1996; Srivastava
et al, 1998). 
Poly (ADP) ribose polymerase (PARP) is a chromatin-associ-
ated enzyme which, in response to DNA damage, binds rapidly
to DNA strand breaks and undergoes automodification by
forming long, branched poly (ADP-ribose) polymers (Sims et al,
1983; Lindahl et al, 1995). Although MCF-7 cells do not express
caspase 3 that involve the cleavage of PARP (Janicke et al,
1408 XM Liu et al
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Figure 7 Effects of MAP kinase inhibitor, PD98059, on the vinorelbine-mediated ERK2 kinase activation. MCF-7 cells grown exponentially were treated for
24 h with 0.1 µ M of vinorelbine (NVB) in the presence of indicated concentrations of PD98059. The cells were harvested, washed, and total protein extracted for
determination of levels of bcl-2, bax and PARP by Western blotting (upper panels), and quantitated by an Imaging densitometer (lower panel), and normalized
by β -actin. The lower panel presents results of means ± SD obtained from three separate experiments. *: P < 0.01 1998), the selective cleavage of PARP by several other caspases
is an important event during apoptosis since PARP cleavage and
inactivation, as well as subsequent apoptotic process, are termi-
nated by a peptide inhibitor of this protein (Sims et al, 1983;
Kaufmann et al, 1993; Lazebnik et al, 1994; Lindahl et al, 1995;
Tewari et al, 1995; Janicke et al, 1998; Germain et al, 1999;
Rossini et al, 2001). In this study we found that the level of PARP
p116 protein decreased rapidly and significantly following the treat-
ment of MCF-7 cells with either vinorelbine or paclitaxel, which
paralleled the activation of caspase 7 and DNA fragmentation.
These data indicate that apoptosis induced by antimicrotubule
drugs occurred very quickly, and that the activation of PARP
protein not only serves as an early indicator of apoptosis medi-
ated by DNA damage, but also by microtubule targeting agents. 
MAP kinase subfamilies contain three members: 
1. extracellular signal-regulated protein kinases (ERKs)
2. c-Jun N-terminal kinase/stress-activated protein kinase
(JNK/SAPK)
3. p38 [Wang et al, 1998a]
Previous reports have suggested that JNK/SAPK may be respon-
sible for bcl-2 phosphorylation (Avruch et al, 1994; Attalla et al,
1998; Yamamoto et al, 1999), and that microtubule targeting
agents activate JNK/SAPK through both Ras and apoptosis signal-
regulating kinase (ASK1) pathways in a variety of human cells.
This activation requires interactions with microtubules (Wang
et al, 1998a). The effects of antimicrotubule drugs on MAP kinase
activity during apoptosis have also been reported (Lieu et al, 1998).
In this study a different pattern of ERK2 activation in MCF-7 cells
was observed, depending upon whether cells were exposed to
vinorelbine or paclitaxel. Vinorelbine rapidly activated ERK2 kinase
whereas paclitaxel inhibited the enzyme activity, a finding consistent
with a previous report (Nishio et al, 1995). This process of activa-
tion/inactivation of ERK2 by the microtubule targeting agents is not
consistent with the induction of bcl-2 phosphorylation by those drugs.
No bcl-2 phosphorylation was observed when immuno-purified bcl-2
proteins were reacted directly with pure ERK2. Moreover, treatment
of MCF-7 cells with PD 98059, a specific ERK2/p38 inhibitor
(Alessi et al, 1995), did not block vinorelbine-induced bcl-2 phos-
phorylation. These data provide new evidence that ERK2 and p38
are not involved in antimicrotubule agent-mediated bcl-2 phospho-
rylation and apoptosis (Yamamoto et al, 1999), even though we
cannot rule out the possibility of other MAP kinases being involved
in vinorelbine-induced bcl-2 phosphorylation. 
The functions of microtubule-associated proteins and filaments
in microtubular assembly are regulated through their phosphoryla-
tion by MAP kinases and/or p34cdc2 (Raffaelli et al, 1992).
Microtubule-associated proteins are good substrates for ERKs,
and phosphorylation weakens their stabilizing effects on micro-
tubule (Hirokawa, 1994). A differential effect of microtubule-
targeting agents on MAP kinase activity during induction of
apoptosis has been reported (Nishio et al, 1995). Previous studies
have demonstrated that paclitaxel induces apoptosis through its
inhibition of MAP kinase and p34cdc2 kinase activation at G2/M
phase in PC-9 and PC-14 cell lines (Nishio et al, 1995; Lieu et al,
1998). This decrease in MAP kinase and p34cdc2 kinase activities
parallels the increased complex formation between microtubule-
associated proteins with α - and β -tubulin, with an increase in the
phosphorylation of microtubule-associated protein-2 (Nishio et al,
1995). Thus, activation or inactivation of microtubule targeting
agents on ERK-2 kinase activity may depend upon whether the
drug promotes polymerization or depolymerization. This effect
may also be due to different binding sites of these drugs on micro-
tubules, which then triggers distinct damage of microtubule struc-
tures and signal transduction pathways leading to apoptosis. 
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